Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma.
Reinartz R, Wang S, Kebir S, Silver DJ, Wieland A, Zheng T, Küpper M, Rauschenbach L, Fimmers R, Shepherd TM, Trageser D, Till A, Schäfer N, Glas M, Hillmer AM, Cichon S, Smith AA, Pietsch T, Liu Y, Reynolds BA, Yachnis A, Pincus DW, Simon M, Brüstle O, Steindler DA, Scheffler B. Reinartz R, et al. Among authors: wieland a. Clin Cancer Res. 2017 Jan 15;23(2):562-574. doi: 10.1158/1078-0432.CCR-15-2089. Epub 2016 Aug 12. Clin Cancer Res. 2017. PMID: 27521447 Free PMC article.
Anticancer effects of niclosamide in human glioblastoma.
Wieland A, Trageser D, Gogolok S, Reinartz R, Höfer H, Keller M, Leinhaas A, Schelle R, Normann S, Klaas L, Waha A, Koch P, Fimmers R, Pietsch T, Yachnis AT, Pincus DW, Steindler DA, Brüstle O, Simon M, Glas M, Scheffler B. Wieland A, et al. Clin Cancer Res. 2013 Aug 1;19(15):4124-36. doi: 10.1158/1078-0432.CCR-12-2895. Clin Cancer Res. 2013. PMID: 23908450
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, Trageser D, Till A, Lorbeer FK, Wieland A, Wilhelm-Buchstab T, Ahmad A, Fröhlich H, Cima I, Prasad S, Matschke J, Jendrossek V, Remke M, Grüner BM, Roesch A, Siveke JT, Herold-Mende C, Blau T, Keyvani K, van Landeghem FKH, Pietsch T, Felsberg J, Reifenberger G, Weller M, Sure U, Brüstle O, Simon M, Glas M, Scheffler B. Kebir S, et al. Among authors: wieland a. Clin Cancer Res. 2023 Jan 17;29(2):488-500. doi: 10.1158/1078-0432.CCR-22-0611. Clin Cancer Res. 2023. PMID: 36239995 Free PMC article.
Targeting the cytosolic innate immune receptors RIG-I and MDA5 effectively counteracts cancer cell heterogeneity in glioblastoma.
Glas M, Coch C, Trageser D, Dassler J, Simon M, Koch P, Mertens J, Quandel T, Gorris R, Reinartz R, Wieland A, Von Lehe M, Pusch A, Roy K, Schlee M, Neumann H, Fimmers R, Herrlinger U, Brüstle O, Hartmann G, Besch R, Scheffler B. Glas M, et al. Among authors: wieland a. Stem Cells. 2013 Jun;31(6):1064-74. doi: 10.1002/stem.1350. Stem Cells. 2013. PMID: 23390110
Phase I trial of dovitinib (TKI258) in recurrent glioblastoma.
Schäfer N, Gielen GH, Kebir S, Wieland A, Till A, Mack F, Schaub C, Tzaridis T, Reinartz R, Niessen M, Fimmers R, Simon M, Coch C, Fuhrmann C, Herrlinger U, Scheffler B, Glas M. Schäfer N, et al. Among authors: wieland a. J Cancer Res Clin Oncol. 2016 Jul;142(7):1581-9. doi: 10.1007/s00432-016-2161-0. Epub 2016 Apr 21. J Cancer Res Clin Oncol. 2016. PMID: 27100354 Clinical Trial.
Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma.
Rauschenbach L, Wieland A, Reinartz R, Kebir S, Till A, Darkwah Oppong M, Dobersalske C, Ullrich V, Ahmad A, Jabbarli R, Pierscianek D, Fröhlich H, Simon M, Brüstle O, Sure U, Glas M, Scheffler B. Rauschenbach L, et al. Among authors: wieland a. Eur J Cancer. 2020 Nov;140:130-139. doi: 10.1016/j.ejca.2020.09.017. Epub 2020 Oct 19. Eur J Cancer. 2020. PMID: 33091717
175 results